Side-by-side · Research reference
MatrixylvsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED9/39 cited
BFDA-ApprovedFlagship27/68 cited
Matrixyl
Cosmeceutical Pentapeptide · Topical Anti-Aging
Topical · Dermal · Twice Daily
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
Matrixyl
Tesamorelin
Primary target
Dermal fibroblastsPaccola 2025
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
—
Yes — physiological pulsatility preserved
Origin
Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
02Dosage Protocols
Parameter
Matrixyl
Tesamorelin
Formulation concentration
0.5–5% in topical vehicle
Common cosmeceutical range; higher concentrations in clinical formulations.
—
Application frequency
Twice daily (AM/PM)
Standard cosmeceutical protocol.
—
Duration
8–12 weeks minimum for visible effect
Collagen synthesis requires sustained application.
12–52 weeks
VAT returns within months of stopping.
Vehicle
Serum, cream, or emulsion base
Lipophilic carriers enhance penetration.
—
Frequency
—
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Reconstitution
—
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
—
Empty stomach, pre-sleep preferred
03Metabolic / Fat Loss Evidence
Parameter
Matrixyl
Tesamorelin
Primary fat target
—
Visceral adipose tissue (VAT) — abdominal
Effect on lean mass
—
Modest lean mass preservation / slight increase
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
Matrixyl
Tesamorelin
Irritation
Mild erythema, pruritus in sensitive skin (rare)
—
Allergic reaction
Contact dermatitis (uncommon)
—
Systemic absorption
Negligible — topical application only
—
Injection site reaction
—
Erythema, pruritus, redness (common)
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Antibody formation
—
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
GI symptoms
—
Nausea, diarrhea (mild, transient)
Absolute Contraindications
Matrixyl
- ·Known hypersensitivity to palmitoyl peptides
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
Matrixyl
- ·Active dermatitis or open wounds at application site
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
Matrixyl
Tesamorelin
1. Cleanse
Wash face with gentle cleanser. Pat dry.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Application
Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Timing
Twice daily — morning and evening. Apply before heavier creams or sunscreen.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Storage
Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Needle
—
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
Matrixyl
+ GHK-Cu
Multi-pathwayMatrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.
- Matrixyl
- 0.5–5% topical serum · AM/PM
- GHK-Cu
- 1–2% topical serum · same application
- Frequency
- Twice daily
- Primary benefit
- Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality